Результаты поиска

When the Skin Speaks for the Bone Marrow: Sweet Syndrome and Pancytopenia as the Initial Manifestation of Occult AML.

This case report describes the presentation for a 65-year-old patient with Sweet's syndrome (SS) presenting with systemic symptoms of general weakness, fever, and painful skin lesions on the right arm. He reported a history of weight loss with night sweats, while skin lesions manifested as erythematous plaques and painful papules. The diagnosis was confirmed by skin biopsy, which showed features of significant neutrophilic infiltration on histopathology. Further investigations led to the diagnosis of AML associated with Sweet's syndrome. The study highlights the importance of prompt diagnosis

Совпадение в полном тексте источника
… Malignancy-associated Sweet's syndrome (MASS) may present as a paraneoplastic syndrome in patients with established malignancies or those with occult hematologic neoplasms or solid tumors and is most commonly linked to acute myelogenous leukemia. … A high percentage, approximately 85%, of malignancy-related Sweet's syndrome has been linked to underlying hematologic neoplasms, and the most frequent among them has been acute myeloid leukemia. …

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review.

Haematological malignancies induce important alterations of the immune system, which account for the high frequency of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of haematological

Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling of the bone marrow niche in a manner that promotes malignant over non-malignant hematopoiesis. This take-over of hematopoiesis by the malignant clone is hypothesized to include hyperactivation of inflammatory signaling and overproduction of inflammatory cytokines. In the Ph-negative MPNs, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation

A case of histiocytic sarcoma presenting with primary bone marrow involvement.

Histiocytic sarcoma (HS) is a very rare neoplasm that often shows an aggressive clinical course and systemic symptoms, such as fever, weight loss, adenopathy, hepatosplenomegaly and pancytopenia. It may present as localized or disseminated disease. We describe here a 63-yr-old male who manifested systemic symptoms, including fever, weight loss and generalized weakness. Abdominal and chest computed tomography failed to show specific findings, but there was suspicion of multiple bony changes at the lumbar spine. Fusion whole body positron emission tomography, bone scan and lumbar spine magnetic

Острый панкреатит в качестве первоначального представления метастатического рака груди, вызванного злокачественной гиперкальцемией: доклад по делу.

Острый панкреатит, вызванный гиперкальцемией, является редким заболеванием, которое чаще всего ассоциируется с первичным гиперпаратироидизмом или продвинутыми магнеями, и представляет собой экстренную метаболическую ситуацию. Мы сообщаем о случае 63-year-old Женщина, которая испытывала сильную эпигазную боль в животе, запор и приступы дезориентации. Лабораторные тесты выявили повышенные поджелудочные ферменты и сильную гиперкальцемию. Был диагностирован острейший панкреатит, вторичный до гиперкальцемии, и нормальные уровни паратироидного гормона (PTH) исключали первичный гиперпаратироидизм. Пр

Psychometric properties of the hematopoietic cell transplantation frailty scale: A prospective observational study.

INTRODUCTION: Frailty is common in patients undergoing hematopoietic stem cell transplantation, thereby increasing toxicity risk and reducing post-transplant survival. This study evaluated the psychometric properties of the Hematopoietic Cell Transplantation Frailty Scale to assess transplant candidates. Additionally, it characterized the participants` sociodemographic and clinical profiles. METHODS: One hundred and two patients with hematologic malignancies participated in the study. Reliability was evaluated through internal consistency (Cronbach's alpha), factorial analysis with varimax ro

Совпадение в полном тексте источника
… Introduction Hematopoietic stem cell transplantation (HSCT) is used with curative intentions for hematologic neoplasms and other potentially lethal diseases [ 1 ]. …

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal.

Monoclonal gammopathies of clinical significance (MGCSs) represent a group of diseases featuring the association of a nonmalignant B cells or plasma cells clone, the production of an M-protein, and singularly, the existence of organ damage. They present a current framework that is difficult to approach from a practical clinical perspective. Several points should be addressed in order to move further toward a better understanding. Overall, these entities are only partially included in the international classifications of diseases. Its definition and classification remain ambiguous. Remarkably,

Serious illness conversations and quality of end-of-life care in patients with hematological malignancies-a retrospective quality improvement study.

PurposePatients with hematological malignancies frequently receive aggressive, poor-quality end-of-life care. In oncology, serious illness conversations conducted early in the illness trajectory, focusing on patients' goals, values, and priorities, have been associated with improved end-of-life care and decreased symptoms of anxiety and depression. Yet, evidence of such supportive interventions' impact in hematology remains limited. This study explores the association between receiving a serious illness conversation and the quality of end-of-life care and the timing of serious illness conversa

Cancer, more than a "COVID-19 co-morbidity".

Patients with cancer represent a particularly vulnerable population at risk of adverse outcomes related to COVID-19. Collectively, the initial studies, including patients with and without cancer, confirmed that patients with cancer had a higher risk of complications and death related to COVID-19. Subsequent studies on patients with COVID-19 and cancer investigated patient and disease-related factors associated with COVID-19 severity and morality. Multiple interconnected factors include demographics, comorbidities, cancer-associated variables, treatment side effects, and other parameters. Howev

Partnership, sexuality, and fertility-related communication: findings from a register-based study among long-term hematological cancer survivors.

PURPOSE: Even though the number of hematological cancer survivors suffering from long-term and late consequences of their disease is growing, knowledge about their situation regarding partnership, sexuality, and fertility-related communication is sparse to date. METHODS: We recruited survivors of hematological malignancies (≥ 3 years after diagnosis) from two cancer registries in Germany. We applied validated instruments and study-specific items on satisfaction with partnership, sexual functioning, and fertility-related communication with physicians. We provided descriptive statistics and con

Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases.

Janus kinase inhibitors (JAKi) have undergone three decades of research and development, demonstrating substantial therapeutic efficacy and broad clinical applicability in autoimmune diseases, inflammatory disorders, hematopoietic malignancies, and a spectrum of rare diseases. However, their research and development are constrained by three key challenges: the difficulty in target selection and safety concerns arising from their effects on cellular signaling pathways, as well as the challenges in formulating optimal dosing regimens due to interindividual variability in pharmacokinetics. In thi

Hematologic malignancies magnify the effect of body mass index on insulin resistance in cancer survivors.

Cancer survivors are at increased risk of type 2 diabetes, which usually develops from obesity and insulin resistance. Whether diabetes susceptibility is due to shared risk factors for cancer and insulin resistance or directly related to cancer and its treatment is unknown. We investigated effect modification between malignancy and body mass index (BMI) as determinants of insulin sensitivity in patients with hematologic malignancies and controls without cancer. In a cross-sectional study of 43 individuals without diabetes (20 patients with treated hematologic malignancies; 23 controls without

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.

In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. Th

Gallbladder крупногабаритная нейроэндокринная карцинома у пациента с множественной миеломой: отчет о деле и обзор литературы.

Большой нейроэндокринный карцинома (GB-LCNEC), крайне редкий патологический подтип желчного пузырька, характеризуется высокой агрессивностью и коварным наступлением, часто приводящим к плохому прогнозу и возникновению серьезных проблем в области клинического управления. В настоящем докладе представлен полный курс лечения пациента с диагнозом GB-LCNEC, осложненным активными Multieloma (MM), сопровождаемый систематическим обзором соответствующей литературы, опубликованной за последнее десятилетие. Предварительная съемка выявила желчный пузырь, который был патологически подтвержден в качестве GB-

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.

BackgroundCurrently, three chimeric antigen receptor (CAR)-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have been approved by the U.S. Food and Drug Administration for the treatment of large B cell lymphoma, which provide a novel and promising choice for patients with relapsed or refractory to traditional anti-tumor treatments. Thus, it is pertinent to describe the efficacy and safety profile of the three products available by summarizing the current evidence.MethodsTwo reviewers independently searched the Embase, PubMed, Web of Science, and Cochrane

Cytokine-induced killer cells: new insights for therapy of hematologic malignancies.

BackgroundCytokine-induced killer (CIK) cells are a novel subgroup of immune effectors, classified as one of the modified T cell-mediated arms for immunotherapy. These cells exert MHC-unrestricted cytotoxicity against both hematological and solid malignancies with low incidence of treatment-related severe complications. This study reviews the application of CIK cells in treating cases with hematologic malignancies.Main bodyCIK cells consist of CD3+/CD56+ natural killer (NK) T cells, CD3-/CD56+ NK cells, and CD3+/CD56- cytotoxic T cells. In this regard, the CD3+/CD56+ NK T cells are the primary

A case of acute promyelocytic leukemia concomitant with plasma cell myeloma.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.

BackgroundMyelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent cytopenias may not meet minimal diagnostic criteria for MDS but an alternate diagnosis is not apparent; the term idiopathic cytopenia of undetermined significance (ICUS) has been used to describe this state. MDS and AML occur primarily in older patients who are often treated outside the clinical trial setting. Consequently, our understanding of the patterns of diagnostic evaluation, mana

A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.

IntroductionCancer and corresponding available treatments are associated with substantial symptoms and functional limitations. In this context, collection of patient-reported outcomes (PRO) in clinical trials gained special interest and is recommended by regulatory authorities. Within clinical trials framework, PRO may provide evidence to support medicines approval, labeling and marketing claims. This study aims to analyze the existing evidence based on PRO as part of new oncology indications receiving positive opinions issued by the European Medicines Agency (EMA) between 2017 and 2020 and to

Longitudinal effects of inpatient music therapy dosage on pain intensity and opioid utilization among patients with hematologic or oncologic conditions: a retrospective cohort study.

PurposeSeveral studies support the benefits of music therapy (MT) for improving symptoms within a single session among patients with hematologic/oncologic conditions, but none have examined real-world longitudinal impacts. This study evaluated whether there was a dose-response relationship between MT intervention exposure and longitudinal changes in pain intensity and opioid utilization.MethodsA retrospective electronic health record review was conducted of 283 hospital admissions among adult patients with hematologic/oncologic conditions who received MT and either reported pain ≥ 4/10 on the